Tillotts Pharma AG and Numab AG have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). TNF-α is a cell signaling protein involved in the body’s immune system. When overproduced, it is associated with IBD, a group of conditions consisting of ulcerative colitis and Crohn’s disease that affects up to five million people worldwide. Ant...